Vortioxetine: First Global Approval

Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats

(2013) Yan Li et al.   BEHAVIOURAL BRAIN RESEARCH

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant

(2013) Grace Chen et al.   CLINICAL DRUG INVESTIGATION

A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition

(2013) E L Theunissen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

P.2.b.011 Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder

(2013) G. Filippov et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

P.1.g.014 Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms

(2013) A. Pehrson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

P.2.e.001 Single dose vortioxetine or ketamine but not fluoxetine increases expression of neuroplasticity related genes in the rat prefrontal cortex

(2013) K.G. Du Jardin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

P.2.e.003 Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine

(2013) M.S. Riga et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

P.2.e.004 Vortioxetine (Lu AA21004) disinhibits pyramidal cell output and enhances theta rhythms and long-term plasticity in the hippocampus

(2013) E. Dale et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

P.2.f.029 A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment

(2013) L. Häggström et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects

(2013) Per Stenkrona et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Multi-modality: a new approach for the treatment of major depressive disorder

(2013) Elliott Richelson   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice

(2013) Jean-Philippe Guilloux et al.   NEUROPHARMACOLOGY

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats

(2013) Arne Mørk et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

(2012) David S. Baldwin et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

(2012) Atul R. Mahableshwarkar et al.   CURRENT MEDICAL RESEARCH AND OPINION

P.2.h.002 Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition

(2012) N. Haddjeri et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States

(2012) Anthony J. Rothschild et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

(2012) Leszek Bidzan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

P.2.c.010 The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder

(2012) I. Florea et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—A rat microdialysis and electrophysiology study

(2012) Alan L. Pehrson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder

(2012) David S. Baldwin et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism

(2012) Cécile Bétry et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

(2012) Rakesh Jain et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder

(2012) Neven Henigsberg et al.   JOURNAL OF CLINICAL PSYCHIATRY

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

(2012) Jean-Philippe Boulenger et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects

(2011) Johan Areberg et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Biosynthesis and Identification of an N-Oxide/N-Glucuronide Metabolite and First Synthesis of an N-O-Glucuronide Metabolite of Lu AA21004

(2011) H. K. Uldam et al.   DRUG METABOLISM AND DISPOSITION

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

(2011) David S. Baldwin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

P.2.d.017 Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders

(2009) A. Mørk et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY